Embodiment provided herein are directed to microneedle patches for agent application on a mammal skin. The microneedle patch may comprise a patch scaffold having a surface, and a plurality of microneedles disposed on the surface. Each of the microneedles may be capable of piercing the skin 50 μm to 1000 μm deep, and comprises a composite material comprising polyvinylpyrrolidone (PVP) and one or more additional copolymers selected from the group consisting of maltose, leucine, and dileucine.

The present invention provides a gastrointestinal tract positioning switch, a method of manufacturing the gastrointestinal tract positioning switch and a site-specific delivery capsule. The gastrointestinal tract positioning switch includes a base, a first electrode, a second electrode, a conductive device and a positioning film. The first electrode and the second electrode are spaced apart from each other and fixed on the base. The first electrode and the second electrode electrically connected to the conductive device respectively, and covered by the positioning film. Both the first electrode and the second electrode are an inert electrode, and can be exposed after dissolution or/and degradation of the positioning film in the stomach or intestine.

Transdermal therapeutic systems are described which have at least one electronic component, as well as methods for producing this type of transdermal therapeutic systems.

Various embodiments of the present disclosure include a consumable capsule containing an active ingredient in at least one compartment movably sealed by a stimuli responsive actuator, and an activation device configured to communicate with the consumable capsule. The activation device is configured to emit a wireless signal to activate the stimuli responsive actuator of the consumable capsule, and the consumable capsule is configured to deliver the active ingredient into an external environment based on the activation of the stimuli responsive actuator. In an example, the active ingredient is released into the external environment, whereas in another example, the active ingredient is injected into the external environment.

Described herein in part are silanol based therapeutic payloads comprising a silanol terminus, a divalent spacer moiety, and a drug moiety capable of effecting a target cell or tissue.

Microdevices containing a chamber bound on one side by a nanoporous membrane are provided. The nanoporous membrane may contain hollow nanotubes that extend through the nanoporous membrane, from one surface to the other, and extend beyond the surface of the nanoporous membrane opposite the surface interfacing with the chamber. The nanotubes may provide a fluidic conduit between an environment external to the microdevice and the chamber, which is otherwise substantially fluid-tight. Also provided are methods of making a microdevice and methods of using the microdevices.

Embodiment provided herein are directed to microneedle patches for agent application on a mammal skin. The microneedle patch may comprise a patch scaffold having a surface, and a plurality of microneedles disposed on the surface. Each of the microneedles may be capable of piercing the skin 50 μm to 1000 μm deep, and comprises a composite material comprising polyvinylpyrrolidone (PVP) and one or more additional copolymers selected from the group consisting of maltose, leucine, and dileucine.

[Problem] To provide: an actually effective therapeutic method which is for dementia of Alzheimer's disease, and which is a causal treatment rather than a symptomatic treatment; and a therapeutic substance for dementia of Alzheimer's disease. [Solution] This substance alleviates symptoms such as dementia of Alzheimer's disease by overexpressing a microtubule-associated protein 1B gene in intracerebral neurons. In addition, as methods to solve the problem above, there are mainly two methods: a method for intracerebral administration of a gene therapy vector bound to a microtubule-associated protein 1B gene; and a method for binding a microtubule-associated protein 1B gene to a blood-brain barrier (BBB) permeable nanomachine and administering intravascularly.

Electromechanical substance delivery devices are provided which implement low-power electromechanical release mechanisms for controlled delivery of substances such as drugs and medication. For example, an electromechanical device includes a substrate having a cavity formed in a surface of the substrate, a membrane disposed on the surface of the substrate covering an opening of the cavity, and a seal disposed between the membrane and the surface of the substrate. The seal surrounds the opening of the cavity, and the seal and membrane are configured to enclose the cavity and retain a substance within the cavity. An electrode structure is configured to locally heat a portion of the membrane in response to a control voltage applied to the electrode structure, and create a stress that causes a rupture in the locally heated portion of the membrane to release the substance from within the cavity.

This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immune modulatory agent (e.g., a CD40/CD40L inhibitor).